| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90f4ee566d9768b969cde8b1de75ad0d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42 |
| filingDate |
2008-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3597be725df7a2bca1a319c098913e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fce7b8e12a2ebf93e400b2d393d99f01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffc6a29f4762e1850a528e2f48689e2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11b2ba81a6672ef5adae487a70ddb01b |
| publicationDate |
2010-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2178847-A2 |
| titleOfInvention |
Process for preparing pyrimidine derivatives |
| abstract |
The present invention relates to a process for preparing pyrimidine derivatives of the formula (V), in particular as intermediates useful for preparing pyrimidine derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, such as HMG-CoA reductase inhibitors, e.g. rosuvastatin. NMeSO2Me group or a group capable of being converted into a wherein Z is a -NMeSO2Me group |
| priorityDate |
2007-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |